# Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis

> **NCT07377838** · PHASE3 · NOT_YET_RECRUITING · sponsor: **EHL Bio Co., Ltd.** · enrollment: 286 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** ADSTEM Inj.
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07377838
- **Lead sponsor:** EHL Bio Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2029-06
- **Final completion:** 2029-12
- **Target enrollment:** 286 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07377838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07377838, "Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT07377838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*